9 results on '"Fyles, Anthony W"'
Search Results
2. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX.
- Author
-
Iakovlev, Vladimir V., Pintilie, Melania, Morrison, Andrew, Fyles, Anthony W., Hill, Richard P., and Hedley, David W.
- Published
- 2007
- Full Text
- View/download PDF
3. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.
- Author
-
Mileshkin, Linda R, Moore, Kathleen N, Barnes, Elizabeth H, Gebski, Val, Narayan, Kailash, King, Madeleine T, Bradshaw, Nathan, Lee, Yeh Chen, Diamante, Katrina, Fyles, Anthony W, Small, William, Gaffney, David K, Khaw, Pearly, Brooks, Susan, Thompson, J Spencer, Huh, Warner K, Mathews, Cara A, Buck, Martin, Suder, Aneta, and Lad, Thomas E
- Subjects
- *
CLINICAL trials , *ADJUVANT chemotherapy , *CHEMORADIOTHERAPY , *RECTAL cancer , *CERVICAL cancer , *EXTERNAL beam radiotherapy - Abstract
Standard treatment for locally advanced cervical cancer is chemoradiotherapy, but many patients relapse and die of metastatic disease. We aimed to determine the effects on survival of adjuvant chemotherapy after chemoradiotherapy. The OUTBACK trial was a multicentre, open-label, randomised, phase 3 trial done in 157 hospitals in Australia, China, Canada, New Zealand, Saudi Arabia, Singapore, and the USA. Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease), Eastern Cooperative Oncology Group performance status 0–2, and adequate bone marrow and organ function. Participants were randomly assigned centrally (1:1) using a minimisation approach and stratified by pelvic or common iliac nodal involvement, requirement for extended-field radiotherapy, FIGO 2008 stage, age, and site to receive standard cisplatin-based chemoradiotherapy (40 mg/m2 cisplatin intravenously once-a-week for 5 weeks, during radiotherapy with 45·0–50·4 Gy external beam radiotherapy delivered in fractions of 1·8 Gy to the whole pelvis plus brachytherapy; chemoradiotherapy only group) or standard cisplatin-based chemoradiotherapy followed by adjuvant chemotherapy with four cycles of carboplatin (area under the receiver operator curve 5) and paclitaxel (155 mg/m2) given intravenously on day 1 of a 21 day cycle (adjuvant chemotherapy group). The primary endpoint was overall survival at 5 years, analysed in the intention-to-treat population (ie, all eligible patients who were randomly assigned). Safety was assessed in all patients in the chemoradiotherapy only group who started chemoradiotherapy and all patients in the adjuvant chemotherapy group who received at least one dose of adjuvant chemotherapy. The OUTBACK trial is registered with ClinicalTrials.gov , NCT01414608 , and the Australia New Zealand Clinical Trial Registry, ACTRN12610000732088. Between April 15, 2011, and June 26, 2017, 926 patients were enrolled and randomly assigned to the chemoradiotherapy only group (n=461) or the adjuvant chemotherapy group (n=465), of whom 919 were eligible (456 in the chemoradiotherapy only group and 463 in the adjuvant chemotherapy group; median age 46 years [IQR 37 to 55]; 663 [72%] were White, 121 [13%] were Black or African American, 53 [6%] were Asian, 24 [3%] were Aboriginal or Pacific islander, and 57 [6%] were other races) and included in the analysis. As of data cutoff (April 12, 2021), median follow-up was 60 months (IQR 45 to 65). 5-year overall survival was 72% (95% CI 67 to 76) in the adjuvant chemotherapy group (105 deaths) and 71% (66 to 75) in the chemoradiotherapy only group (116 deaths; difference 1% [95% CI –6 to 7]; hazard ratio 0·90 [95% CI 0·70 to 1·17]; p=0·81). In the safety population, the most common clinically significant grade 3–4 adverse events were decreased neutrophils (71 [20%] in the adjuvant chemotherapy group vs 34 [8%] in the chemoradiotherapy only group), and anaemia (66 [18%] vs 34 [8%]). Serious adverse events occurred in 107 (30%) in the adjuvant chemotherapy group versus 98 (22%) in the chemoradiotherapy only group, most commonly due to infectious complications. There were no treatment-related deaths. Adjuvant carboplatin and paclitaxel chemotherapy given after standard cisplatin-based chemoradiotherapy for unselected locally advanced cervical cancer increased short-term toxicity and did not improve overall survival; therefore, it should not be given in this setting. National Health and Medical Research Council and National Cancer Institute. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update.
- Author
-
Small, William, Bosch, Walter R., Harkenrider, Mathew M., Strauss, Jonathan B., Abu-Rustum, Nadeem, Albuquerque, Kevin V., Beriwal, Sushil, Creutzberg, Carien L., Eifel, Patricia J., Erickson, Beth A., Fyles, Anthony W., Hentz, Courtney L., Jhingran, Anuja, Klopp, Ann H., Kunos, Charles A., Mell, Loren K., Portelance, Lorraine, Powell, Melanie E., Viswanathan, Akila N., and Yacoub, Joseph H.
- Subjects
- *
CERVICAL cancer , *ENDOMETRIAL cancer , *RADIOTHERAPY , *ESTIMATION theory , *GYNECOLOGIC cancer , *CANCER , *IMAGE-guided radiation therapy - Abstract
Purpose: Accurate target definition is critical for the appropriate application of radiation therapy. In 2008, the Radiation Therapy Oncology Group (RTOG) published an international collaborative atlas to define the clinical target volume (CTV) for intensity modulated pelvic radiation therapy in the postoperative treatment of endometrial and cervical cancer. The current project is an updated consensus of CTV definitions, with removal of all references to bony landmarks and inclusion of the para-aortic and inferior obturator nodal regions.Methods and Materials: An international consensus guideline working group discussed modifications of the current atlas and areas of controversy. A document was prepared to assist in contouring definitions. A sample case abdominopelvic computed tomographic image was made available, on which experts contoured targets. Targets were analyzed for consistency of delineation using an expectation-maximization algorithm for simultaneous truth and performance level estimation with kappa statistics as a measure of agreement between observers.Results: Sixteen participants provided 13 sets of contours. Participants were asked to provide separate contours of the following areas: vaginal cuff, obturator, internal iliac, external iliac, presacral, common iliac, and para-aortic regions. There was substantial agreement for the common iliac region (sensitivity 0.71, specificity 0.981, kappa 0.64), moderate agreement in the external iliac, para-aortic, internal iliac and vaginal cuff regions (sensitivity 0.66, 0.74, 0.62, 0.59; specificity 0.989, 0.966, 0.986, 0.976; kappa 0.60, 0.58, 0.52, 0.47, respectively), and fair agreement in the presacral and obturator regions (sensitivity 0.55, 0.35; specificity 0.986, 0.988; kappa 0.36, 0.21, respectively). A 95% agreement contour was smoothed and a final contour atlas was produced according to consensus.Conclusions: Agreement among the participants was most consistent in the common iliac region and least in the presacral and obturator nodal regions. The consensus volumes formed the basis of the updated NRG/RTOG Oncology postoperative atlas. Continued patterns of recurrence research are encouraged to refine these volumes. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
5. The Significance of Tumoral ERCC1 Status in Patients With Locally Advanced Cervical Cancer Treated With Chemoradiation Therapy: A Multicenter Clinicopathologic Analysis
- Author
-
Doll, Corinne M., Aquino-Parsons, Christina, Pintilie, Melania, Klimowicz, Alexander C., Petrillo, Stephanie K., Milosevic, Michael, Craighead, Peter S., Clarke, Blaise, Lees-Miller, Susan P., Fyles, Anthony W., and Magliocco, Anthony M.
- Subjects
- *
CERVICAL cancer patients , *CERVICAL cancer treatment , *SURGICAL excision , *CANCER chemotherapy , *CANCER radiotherapy , *CLINICAL pathology , *CISPLATIN - Abstract
Purpose: ERCC1 (excision repair cross-complementation group 1) expression has been shown to be a molecular marker of cisplatin resistance in many tumor sites, but has not been well studied in cervical cancer patients. The purpose of this study was to measure tumoral ERCC1 in patients with locally advanced cervical cancer treated with chemoradiation therapy (CRT) in a large multicenter cohort, and to correlate expression with clinical outcome parameters. Methods and Materials: A total of 264 patients with locally advanced cervical cancer, treated with curative-intent radical CRT from 3 major Canadian cancer centers were evaluated. Pretreatment formalin-fixed, paraffin-embedded tumor specimens were retrieved, and tissue microarrays were constructed. Tumoral ERCC1 (FL297 antibody) was measured using AQUA (R) technology. Statistical analysis was performed to determine the significance of clinical factors and ERCC1 status with progression-free survival (PFS) and overall survival (OS) at 5 years. Results: The majority of patients had International Federation of Gynecology and Obstetrics (FIGO) stage II disease (n=119, 45%); median tumor size was 5 cm. OS was associated with tumor size (HR 1.16, P=.018), pretreatment hemoglobin status (HR 2.33, P=.00027), and FIGO stage. In addition, tumoral ERCC1 status (nuclear to cytoplasmic ratio) was associated with PFS (HR 2.33 [1.05-5.18], P=.038) and OS (HR 3.13 [1.27-7.71], P=.013). ERCC1 status was not significant on multivariate analysis when the model was adjusted for the clinical factors: for PFS (HR 1.49 [0.61-3.6], P=.38); for OS (HR 2.42 [0.94-6.24] P=.067). Conclusions: In this large multicenter cohort of locally advanced cervical cancer patients treated with radical CRT, stage, tumor size, and pretreatment hemoglobin status were significantly associated with PFS and OS. ERCC1 status appears to have prognostic impact on univariate analysis in these patients, but was not independently associated with outcome on multivariate analysis. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
6. Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ
- Author
-
Williamson, Deborah, Dinniwell, Robert, Fung, Sharon, Pintilie, Melania, Done, Susan J., and Fyles, Anthony W.
- Subjects
- *
ADJUVANT treatment of cancer , *LUMPECTOMY , *DUCTAL carcinoma , *CANCER radiotherapy , *REGRESSION analysis , *TREATMENT effectiveness - Abstract
Abstract: Purpose: Adjuvant whole breast radiotherapy (WBRT) for ductal carcinoma in situ (DCIS) improves local control, however an optimal dose fractionation remains undefined. WBRT following breast-conserving surgery for invasive breast cancer demonstrates equivalent efficacy and morbidity for conventional and hypofractionated treatment. Our group policy allowed for the use of both schedules, therefore we compared local control in women with DCIS following breast-conserving surgery. Patients and methods: Two hundred and sixty-six patients treated between January 1999 and December 2004 with conventional (50Gy in 25 fractions) or hypofractionated (42.4Gy in 16 fractions or 40Gy/16+12.5Gy boost) WBRT after breast-conserving surgery for DCIS were retrospectively reviewed. Median follow-up was 3.76years (range 0.1–8.9years). Results: One hundred and four patients (39%) were treated with conventional and 162 (61%) with hypofractionated WBRT. The median age was 56.7years (range 32.2–83.8years), and prognostic features were well matched in both groups, apart from a small increase in tumour size in the conventional arm (1.75 vs. 2.12cm, p =0.05). Actuarial risk of recurrence at 4years was 7% with hypofractionated WBRT and 6% with the conventional schedule (p =0.9). Univariate analysis showed an increased risk of recurrence with high nuclear grade tumours (11% at 4years for grade 3 vs. 4% for grade 1/2, p =0.029). Conclusions: Hypofractionated adjuvant WBRT following breast-conserving surgery for DCIS has comparable local control to a conventional radiation schedule. Hypofractionated WBRT is more convenient for patients, has equivalent morbidity and should be considered in this patient group. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
7. Estimating hypoxic status in human tumors: A simulation using Eppendorf oxygen probe data in cervical cancer patients
- Author
-
Doll, Corinne M., Milosevic, Michael, Pintilie, Melania, Hill, Richard P., and Fyles, Anthony W.
- Subjects
- *
HYPOXEMIA , *OXYGEN analysis , *ADENOCARCINOMA , *BIOLOGICAL models , *CELL physiology , *COMPARATIVE studies , *COMPUTER simulation , *DIAGNOSTIC errors , *ELECTRODES , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *POLAROGRAPHY , *PROGNOSIS , *RESEARCH , *SQUAMOUS cell carcinoma , *EVALUATION research , *PREDICTIVE tests , *PARTIAL pressure ,CERVIX uteri tumors ,EPITHELIAL cell tumors ,RESEARCH evaluation - Abstract
: PurposeTo define the minimal number of pO2 measurements, with 90% sensitivity and 90% specificity, needed to categorize cervical tumors as either hypoxic or oxic.: Methods and materialsUsing Eppendorf oxygen probe data from our ongoing prospective trial, we simulated the measurement of tumor oxygenation with a smaller number of data points in 135 patients with cervical cancer. The hypoxic proportion, defined as the percentage of pO2 values <5 mm Hg (HP5), was calculated for each tumor. Hypoxic tumors were defined as those with a median HP5 >50%, and tumors with normal oxygen levels as those with a median HP5 ≤50%. A small number of pO2 measurements were randomly selected from the Eppendorf measurements in each tumor, or per Eppendorf track, and used to define the tumor as hypoxic or oxic. The sensitivity and specificity were calculated, considering the classification as given by the complete set of Eppendorf measurements as the reference standard.: ResultsThe probability of falsely classifying the tumor decreased as the selected number of pO2 measurements per tumor increased, and at 16 measurements was approximately 10%. Adding additional measurements per tumor beyond 24 improved the ability to classify the tumor accurately only slightly. The probability of falsely classifying the tumor decreased as the pO2 measurements per track increased. At five measurements per track, the probability of falsely classifying the tumor was approximately 9%.: ConclusionApproximately 20 measurements per tumor, or five measurements per track, using the Eppendorf pO2 histograph, are sufficient to categorize cervical tumors as hypoxic or oxic. The results of this study will serve as a guide for research clinicians in the use of this and other systems in the assessment of tumor oxygenation in humans. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
8. Prospective comparison of breast pain in patients participating in a randomized trial of breast-conserving surgery and tamoxifen with or without radiotherapy
- Author
-
Rayan, Gamal, Dawson, Laura A., Bezjak, Andrea, Lau, Anthea, Fyles, Anthony W., Yi, Qi-Long, Merante, Pat, and Vallis, Katherine A.
- Subjects
- *
BREAST cancer , *TAMOXIFEN , *RADIOTHERAPY , *QUALITY of life , *BREAST tumor treatment , *RESEARCH , *MCGILL Pain Questionnaire , *PAIN , *CLINICAL trials , *RESEARCH methodology , *SURGICAL complications , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *RANDOMIZED controlled trials , *BREAST , *QUESTIONNAIRES , *COMBINED modality therapy , *LONGITUDINAL method , *BREAST tumors , *CANCER & psychology - Abstract
: To determine whether breast pain affects quality of life (QOL) after breast-conserving surgery and tamoxifen (TAM) with or without adjuvant breast radiotherapy (RT).Purpose : A randomized clinical trial was carried out at the Princess Margaret Hospital between 1992 and 2000 to evaluate the need for breast RT in addition to TAM in women ≥50 years treated with breast-conserving surgery for T1-T2N0 breast cancer. A companion study to assess breast pain was carried out during the last 2 years of the randomized clinical trial. The short-form McGill Pain Questionnaire (SF-MPQ), the European Organization for Research and Treatment of Cancer (EORTC) QOL (QLQ-C30) and EORTC breast cancer module (QLQ-BR23) questionnaires were completed by patients within 1 week of randomization in the randomized clinical trial (baseline) and at 3, 6, and 12 months.Methods and Materials : Eighty-six patients participated in the breast pain study; 41 received RT plus TAM and 45 received TAM alone. The median age was 70 years (range 51–80). The baseline pain and QOL scores were similar for the two groups. No significant difference was found between the two groups for each scale of the QLQ-C30 and QLQ-BR23 questionnaires at 3, 6, or 12 months (p >0.100), except that at 12 months, the score for role function (QLQ-C30) was higher in the RT plus TAM group than in the RT-only group (p = 0.02). At 3 months, the difference between the mean scores for the SF-MPQ was 0.553 (p = 0.47). At 12 months, the pain scores had decreased in both groups; the difference was 0.199 (p = 0.71). The number of breast operations or surgical complications did not correlate with breast pain in either group. Acute RT toxicity scores did not correlate with breast pain or QOL scores at 12 months.Results : These results suggest that breast RT does not significantly contribute to breast pain or adversely impact the QOL up to 12 months after treatment in postmenopausal patients with node-negative breast cancer who take TAM. [Copyright &y& Elsevier]Conclusion - Published
- 2003
- Full Text
- View/download PDF
9. Expression of hypoxia-inducible factor-1α in cervical carcinomas: correlation with tumor oxygenation
- Author
-
Haugland, Hans Kristian, Vukovic, Vojislav, Pintilie, Melania, Fyles, Anthony W., Milosevic, Michael, Hill, Richard P., and Hedley, David W.
- Subjects
- *
HYPOXEMIA , *OXYGEN metabolism , *CANCER , *COMPARATIVE studies , *DIGITAL image processing , *IMMUNOHISTOCHEMISTRY , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *PROTEINS , *RESEARCH , *TIME , *TRANSCRIPTION factors , *EVALUATION research ,CERVICAL vertebrae diseases ,CERVIX uteri tumors - Abstract
Purpose: To investigate the relations between hypoxia-inducible factor-1 (HIF-1), tumor oxygenation, and clinical correlates in patients with locally advanced carcinoma of the uterine cervix.Methods and Materials: Biopsies from 42 patients with invasive cervical carcinoma and previous polarographic O2 measurements were assessed for the expression of HIF-1α using digitized microscopic imaging and analysis.Results: The HIF-1α expression levels ranged from <0.1% to 10.7% of the total tumor area; the positive staining was localized exclusively to the nuclei. Three distinct arrangement patterns of HIF-1α-positive cells in relation to blood vessels were identified using spatial image mapping: (1) most HIF-1α-positive cells were located within the typical oxygen diffusion distance in tissue (≤150 μm to the nearest blood vessel); (2) most HIF-1α-positive cells were located in the vicinity (≤60 μm) of the blood vessels; and (3) no apparent spatial relationship was found between HIF-1α-positive cells and blood vessels. A statistically significant association was found between HIF-1α expression and tumor oxygenation (Spearman correlation coefficient = 0.4, p <0.01), as determined with the Eppendorf pO2 histograph. No correlation was found between the level of HIF-1α expression and patient outcome, using disease-free survival as the end point.Conclusion: Our results suggest that HIF-1α expression may represent a useful biologic marker for hypoxia in uterine cervical cancer. [Copyright &y& Elsevier]- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.